UroGen Pharma (URGN) Competitor Comparison
We are evaluating the key criteria listed to compare UroGen Pharma (URGN) against its competitors in the Biotechnology industry.
Market Capitalization
163 / 368Gross Profits
60 / 278Total Revenue
103 / 300EBITDA
167 / 337Free Cashflow
196 / 352Quick Ratio
149 / 357Earnings per Share
258 / 359Dividend yield
0 / 6Total Cash
186 / 358Performance 3 years
134 / 368Performance 5 years
174 / 368Performance 10 years
110 / 368Linearity 3 years
70 / 368Linearity 5 years
135 / 368Linearity 10 years
10 / 368Total Rank
49 / 368Dividend Rank
295 / 368Valuation Rank
118 / 368Piotroski Rank
120 / 368Muliplier Rank
223 / 368Gross Profits - URGN ranking 60 / 278
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.